Tao Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tao Luo has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Weizhong Tang
Guangxi Medical University Cancer Hospital, China
5 shared publications Jinglian Chen
Colorectal and Anal Disease Unit, Department of Gastrointestinal Surgery, Guangxi Medical University Cancer Hospital, No.71 Hedi Road, Nanning 530021, P.R. China; Guangxi Key Laboratory of Basic and Translational Research for Colorectal Cancer, No.71 Hedi Road, Nanning 530021, P.R. China
4 shared publicationsQiuhua Lin
Colorectal and Anal Disease Unit, Department of Gastrointestinal Surgery, Guangxi Medical University Cancer Hospital, No.71 Hedi Road, Nanning 530021, P.R. China; Guangxi Key Laboratory of Basic and Translational Research for Colorectal Cancer, No.71 Hedi Road, Nanning 530021, P.R. China
4 shared publicationsXinjie Wei
Colorectal and Anal Disease Unit, Department of Gastrointestinal Surgery, Guangxi Medical University Cancer Hospital, No.71 Hedi Road, Nanning 530021, P.R. China; Guangxi Key Laboratory of Basic and Translational Research for Colorectal Cancer, No.71 Hedi Road, Nanning 530021, P.R. China
3 shared publicationsChunyin Wei
Department of Gastrointestinal Surgery, Department of Medical Ultrasound, Department of Breast, Bone & Soft Tissue Oncology, Day Oncology Unit and Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Guangxi Medical University, No. 71 Hedi Road, Nanning, 530021, China
2 shared publications- Duo Wang
Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing 210009, China
2 shared publications
Latest Publications
- Open Access
- 6 May 2025
- Published by Elsevier in Cell Reports
- Vol. 44 (5) , 115681
OTUD4 inhibits ferroptosis by stabilizing GPX4 and suppressing autophagic degradation to promote tumor progression
- 6 May 2025
- Published by Elsevier in Cell Reports
- Vol. 44 (5) , 115681
Open AccessOTUD4 inhibits ferroptosis by stabilizing GPX4 and suppressing autophagic degradation to promote tumor progression
- Open Access
- 25 March 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-21
Dual-modality immune nano-activator harnessing Mn2⁺ and quercetin to potentiate the cGAS-STING pathway for advanced cancer metalloimmunotherapy
Manganese ions (Mn2+) have emerged as promising activators of the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway. However, their clinical application was hindered by low bioavailability and limited immune activation pathways, which impaired their ability to trigger robust immune responses and achieve significant antitumor effects. To address these challenges, we developed a dual-modality immune nano-activator by coordinating manganese ions with quercetin. This strategy was designed to enhance the cGAS-STING pathway activation and elicit the immunogenic cell death, thereby strengthening the antitumor immune response. The engineered nano-activator demonstrated superior tumor-targeting ability and efficient cellular internalization. Upon exposure to near-infrared irradiation, the system harnessed photothermal effects to induce apoptosis in tumor cells while simultaneously accelerating the release of manganese ions and quercetin. The released manganese ions facilitated the generation of reactive oxygen species, which in conjunction with quercetin-induced apoptosis, amplified photothermal-induced DNA damage. This DNA damage further promoted the release of cytosolic DNA, which in turn activated the cGAS-STING pathway, thereby intensifying immune activation. Notably, the nano-activator also triggered immunogenic cell death, which synergized with the cGAS-STING activation to promote dendritic cell maturation and activate antigen-specific T-cell, significantly enhancing the immune response against the tumor. Both in vitro and in vivo studies confirmed that this nano-activator effectively inhibited tumor growth, with particularly pronounced effects when combined with anti-CTLA-4 antibodies.
- 25 March 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-21
Open AccessDual-modality immune nano-activator harnessing Mn2⁺ and quercetin to potentiate the cGAS-STING pathway for advanced cancer metalloimmunotherapy
Manganese ions (Mn2+) have emerged as promising activators of the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway. However, their clinical application was hindered by low bioavailability and limited immune activation pathways, which impaired their ability to trigger robust immune responses and achieve significant antitumor effects. To address these challenges, we developed a dual-modality immune nano-activator by coordinating manganese ions with quercetin. This strategy was designed to enhance the cGAS-STING pathway activation and elicit the immunogenic cell death, thereby strengthening the antitumor immune response. The engineered nano-activator demonstrated superior tumor-targeting ability and efficient cellular internalization. Upon exposure to near-infrared irradiation, the system harnessed photothermal effects to induce apoptosis in tumor cells while simultaneously accelerating the release of manganese ions and quercetin. The released manganese ions facilitated the generation of reactive oxygen species, which in conjunction with quercetin-induced apoptosis, amplified photothermal-induced DNA damage. This DNA damage further promoted the release of cytosolic DNA, which in turn activated the cGAS-STING pathway, thereby intensifying immune activation. Notably, the nano-activator also triggered immunogenic cell death, which synergized with the cGAS-STING activation to promote dendritic cell maturation and activate antigen-specific T-cell, significantly enhancing the immune response against the tumor. Both in vitro and in vivo studies confirmed that this nano-activator effectively inhibited tumor growth, with particularly pronounced effects when combined with anti-CTLA-4 antibodies.
- Open Access
- 9 November 2024
- Published by Elsevier in Materials Today Bio
- Vol. 29, 101326
Orchestrated copper-loaded nanoreactor for simultaneous induction of cuproptosis and immunotherapeutic intervention in colorectal cancer
- 9 November 2024
- Published by Elsevier in Materials Today Bio
- Vol. 29, 101326
Open AccessOrchestrated copper-loaded nanoreactor for simultaneous induction of cuproptosis and immunotherapeutic intervention in colorectal cancer
- Open Access
- 6 November 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (21) , e70397
Isobutyric Acid Promotes Immune Evasion in Colorectal Cancer via Increased PD ‐ L1 Expression
Introduction: Isobutyric acid (IBA), a short‐chain fatty acid, has been unequivocally demonstrated to exert significant influence on the progression of colorectal cancer (CRC). Nevertheless, a comprehensive understanding of its intricate regulatory mechanisms remains elusive. Methods: Employing advanced techniques such as western blot, RT‐qPCR, and flow cytometry, we systematically investigated the impact of IBA on the expression of PD‐L1 in CRC cells. Concurrently, employing RNA silencing technology and small‐molecule inhibitors, we delved into the molecular intricacies underlying the regulatory axis of IBA involving ROCK1/c‐Myc/PD‐L1. Furthermore, through flow cytometry analysis, we examined the alterations in the tumor immune microenvironment following anti‐PD‐L1 antibody therapy in a murine tumor model treated with IBA. Results: Elevated levels of IBA were found to robustly activate PD‐L1 expression in CRC cells both in vitro and in vivo, concomitantly reshaping the tumor immune microenvironment. Subsequent mechanistic investigations unveiled that IBA, through its interaction and activation of ROCK1, promotes the activation of c‐Myc, thereby enhancing the transcription of PD‐L1. Silencing of ROCK1 and application of ROCK1 inhibitors effectively reversed the regulatory effects of IBA on PD‐L1. Additionally, IBA inhibited the activity of infiltrating CD8 + T cells, resulting in diminished antitumor immunity and attenuating the sensitivity to anti‐PD‐L1 therapy. Conclusion: Our study elucidates a novel mechanism by which IBA inhibits the sensitivity of CRC to anti‐PD‐L1 antibody therapy. Emphasizing IBA and its downstream pathways as potential therapeutic targets for immune therapy resistance mechanisms, our findings provide a novel theoretical foundation for overcoming immune therapy resistance.
- 6 November 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (21) , e70397
Open AccessIsobutyric Acid Promotes Immune Evasion in Colorectal Cancer via Increased PD ‐ L1 Expression
Introduction: Isobutyric acid (IBA), a short‐chain fatty acid, has been unequivocally demonstrated to exert significant influence on the progression of colorectal cancer (CRC). Nevertheless, a comprehensive understanding of its intricate regulatory mechanisms remains elusive. Methods: Employing advanced techniques such as western blot, RT‐qPCR, and flow cytometry, we systematically investigated the impact of IBA on the expression of PD‐L1 in CRC cells. Concurrently, employing RNA silencing technology and small‐molecule inhibitors, we delved into the molecular intricacies underlying the regulatory axis of IBA involving ROCK1/c‐Myc/PD‐L1. Furthermore, through flow cytometry analysis, we examined the alterations in the tumor immune microenvironment following anti‐PD‐L1 antibody therapy in a murine tumor model treated with IBA. Results: Elevated levels of IBA were found to robustly activate PD‐L1 expression in CRC cells both in vitro and in vivo, concomitantly reshaping the tumor immune microenvironment. Subsequent mechanistic investigations unveiled that IBA, through its interaction and activation of ROCK1, promotes the activation of c‐Myc, thereby enhancing the transcription of PD‐L1. Silencing of ROCK1 and application of ROCK1 inhibitors effectively reversed the regulatory effects of IBA on PD‐L1. Additionally, IBA inhibited the activity of infiltrating CD8 + T cells, resulting in diminished antitumor immunity and attenuating the sensitivity to anti‐PD‐L1 therapy. Conclusion: Our study elucidates a novel mechanism by which IBA inhibits the sensitivity of CRC to anti‐PD‐L1 antibody therapy. Emphasizing IBA and its downstream pathways as potential therapeutic targets for immune therapy resistance mechanisms, our findings provide a novel theoretical foundation for overcoming immune therapy resistance.
- Open Access
- 31 July 2023
- Published by Wiley in Cancer Science
- Vol. 114 (10) , 3900-3913
Isobutyric acid promotes colorectal cancer metastasis through activating RACK1
Colorectal cancer (CRC) metastasis plays a crucial role in disease progression, yet the regulatory mechanisms underlying metastasis remain incompletely understood. Isobutyric acid (IBA), a short‐chain fatty acid found at high levels in serum of CRC patients, has been shown to be a critical metabolite influencing CRC proliferation. However, its role in tumor metastasis remains unknown. Here, utilizing liquid chromatography tandem mass spectrometry (LC‐MS/MS) analysis, we found that levels of IBA were significantly higher in patients with distant organ metastasis of CRC than in those without. Furthermore, IBA promoted CRC metastasis both in vitro and in vivo. Mass spectrometry, immunofluorescence, and cellular thermal shift assay revealed that IBA interacts with RACK1. Mechanistically, IBA binding to and activating RACK1 promotes regulation of downstream Akt and FAK signaling and CRC metastasis. Collectively, our study highlights the critical interplay between IBA and RACK1 and its impact on tumor metastasis. This study suggests that targeting the IBA–RACK1 signaling axis may be an effective therapeutic strategy for controlling CRC metastasis.
- 31 July 2023
- Published by Wiley in Cancer Science
- Vol. 114 (10) , 3900-3913
Open AccessIsobutyric acid promotes colorectal cancer metastasis through activating RACK1
Colorectal cancer (CRC) metastasis plays a crucial role in disease progression, yet the regulatory mechanisms underlying metastasis remain incompletely understood. Isobutyric acid (IBA), a short‐chain fatty acid found at high levels in serum of CRC patients, has been shown to be a critical metabolite influencing CRC proliferation. However, its role in tumor metastasis remains unknown. Here, utilizing liquid chromatography tandem mass spectrometry (LC‐MS/MS) analysis, we found that levels of IBA were significantly higher in patients with distant organ metastasis of CRC than in those without. Furthermore, IBA promoted CRC metastasis both in vitro and in vivo. Mass spectrometry, immunofluorescence, and cellular thermal shift assay revealed that IBA interacts with RACK1. Mechanistically, IBA binding to and activating RACK1 promotes regulation of downstream Akt and FAK signaling and CRC metastasis. Collectively, our study highlights the critical interplay between IBA and RACK1 and its impact on tumor metastasis. This study suggests that targeting the IBA–RACK1 signaling axis may be an effective therapeutic strategy for controlling CRC metastasis.
- Open Access
- 25 September 2022
- Published by Wiley in Advanced Science
- Vol. 9 (32) , e2203106
Intraparticle Double‐Scattering‐Decoded Sonogenetics for Augmenting Immune Checkpoint Blockade and CAR‐T Therapy
Genetically arming new chimeric antigen receptors (CARs) on T cells is a prevalent method to fulfill CAR‐T immunotherapy. However, this approach fails to completely address the poor infiltration, complex immunosuppressive tumor microenvironment (ITM), and insufficient immune cells, which are recognized as the three dominant hurdles to discouraging the trafficking and persistence of CAR‐T and immune checkpoint blockade (ICB) immunotherapies against solid tumors. To address the three hurdles, a sonoimmunity‐engineered nanoplatform is designed in which a rattle‐type‐structured carrier enables intraparticle‐double‐scattering to generate massive reactive oxygen species (ROS) during the sonodynamic process. Abundant ROS accumulation can directly kill tumor cells, release antigens, and activate systematic immune responses for expanding effector T or CAR‐T cells, while alleviating ITM via immunosuppressive macrophage polarization and reduction in pro‐tumorigenic cytokine secretion. Furthermore, the co‐loaded phosphodiesterase‐5 inhibitors release nitric oxide (NO) to impel vascular normalization and open the infiltration barrier (IB) for allowing more T cells to enter into the tumor. Systematic experiments demonstrate the feasibility of such intraparticle‐double‐scattering‐decoded sonogenetics in the sonoimmunity‐engineered nanoplatforms for expanding effector T or CAR‐T cells, thereby promoting their infiltration into tumors and alleviating ITM. These compelling actions lead to excellent CAR‐T and ICB immunotherapies against solid tumors with repressed tumor metastasis.
- 25 September 2022
- Published by Wiley in Advanced Science
- Vol. 9 (32) , e2203106
Open AccessIntraparticle Double‐Scattering‐Decoded Sonogenetics for Augmenting Immune Checkpoint Blockade and CAR‐T Therapy
Genetically arming new chimeric antigen receptors (CARs) on T cells is a prevalent method to fulfill CAR‐T immunotherapy. However, this approach fails to completely address the poor infiltration, complex immunosuppressive tumor microenvironment (ITM), and insufficient immune cells, which are recognized as the three dominant hurdles to discouraging the trafficking and persistence of CAR‐T and immune checkpoint blockade (ICB) immunotherapies against solid tumors. To address the three hurdles, a sonoimmunity‐engineered nanoplatform is designed in which a rattle‐type‐structured carrier enables intraparticle‐double‐scattering to generate massive reactive oxygen species (ROS) during the sonodynamic process. Abundant ROS accumulation can directly kill tumor cells, release antigens, and activate systematic immune responses for expanding effector T or CAR‐T cells, while alleviating ITM via immunosuppressive macrophage polarization and reduction in pro‐tumorigenic cytokine secretion. Furthermore, the co‐loaded phosphodiesterase‐5 inhibitors release nitric oxide (NO) to impel vascular normalization and open the infiltration barrier (IB) for allowing more T cells to enter into the tumor. Systematic experiments demonstrate the feasibility of such intraparticle‐double‐scattering‐decoded sonogenetics in the sonoimmunity‐engineered nanoplatforms for expanding effector T or CAR‐T cells, thereby promoting their infiltration into tumors and alleviating ITM. These compelling actions lead to excellent CAR‐T and ICB immunotherapies against solid tumors with repressed tumor metastasis.